Danny Yeung is the Co-Founder of Prenetics and has served as Chief Executive Officer since its inception in 2014. Mr. Yeung’s journey into healthcare started as a way to utilize his extensive entrepreneurial career into making an impact for society. Mr. Yeung’s vision from day 1 was to always turn Prenetics into a global health company, recruiting the best talent, and to give everyone the power to be in control of their own health.

Prior to Prenetics, Mr. Yeung was a Founding Partner at SXE Ventures, having led multiple investments in genetic testing companies and in Honey Science, which was acquired by Paypal for US $4 billion in 2019. Mr. Yeung had also founded uBuyiBuy in 2010, which was subsequently acquired by Groupon. Prior to leaving Groupon in early 2014, Mr. Yeung served as CEO of Groupon East Asia, leading it to be the largest e-commerce company in the region. Mr. Yeung’s entrepreneurial journey started at the age of 25 when he ventured into franchising Hong Kong dessert chain “Hui Lau Shan” into the USA. After exiting Hui Lau Shan, Mr. Yeung successfully ventured into hospitality furniture and executed multi-million-dollar projects with MGM globally. Mr. Yeung’s life motto is “Play Hard, Work Harder”.

Stephen has served as the Chief Financial Officer of Prenetics since 2018, and oversees the financial operations, corporate accounting and reporting, treasury, financial and tax planning and analysis and investor relations. Prior to joining Prenetics, Mr. Lo was in the Asia Pacific Investment Banking team of Citigroup, where he worked extensively on initial public offering transactions, placements, debt issuances and cross border mergers and acquisitions in Asia and the U.S. between 2014 and 2018. From 2007 to 2011, Mr. Lo was an auditor with Ernst & Young.

Mr. Lo received a Master of Business Administration from Yale University’s School of Management, a Master of Science in Accounting and Finance from the London School of Economics and Political Science and a bachelor’s degree in Accounting from Hong Kong Baptist University. Mr. Lo is a Fellow of the Hong Kong Institute of Certified Public Accountants, a Chartered Accountant of the Institute of Chartered Accountants in England and Wales and a CFA Charterholder.

Dr. Lawrence Tzang is the Co-Founder of Prenetics and has served as its Chief Scientific Officer and director since its founding in 2014. He has more than 20 years of experience in molecular diagnostics, genomics as well as laboratory automation. Dr. Tzang has been a registered Medical Laboratory Technologist I at the Board of Medical Laboratory Technologist since 2013, a founding member and ex-secretary at the Hong Kong Society for Behavioral and Neural Genetics in 2011-2022 and a fellow of the Hong Kong Society for Molecular Diagnostic Sciences since 2008. Dr. Tzang received his Ph.D. in Molecular Biology in 2003 and post-doctoral research fellowship at Department of Biology & Chemistry of the City University of Hong Kong from 2003 to 2009.

Dr. Tzang used microarray technologies on gene expression profiling for cancer researches, including vimentin and clusterin gene expression in hepatocellular carcinoma metastasis and key role of a protein in hepatocarcinogenesis, as well as drug resistance in cervical carcinoma. Dr. Tzang has also developed a biochip based genotyping platform for human papillomavirus genotyping and prevalence analysis in cervical cancer. In addition, he also participated in deep proteome profiling of sera from never-smoked lung cancer patients.

Joel Neoh is a serial entrepreneur and technology executive with over 15 years of top-flight leadership and board experience. Joel’s experience in consumer technology spans sectors such as fintech, e-commerce, digital media, and health & wellness. Most recently, Joel was the founder of Fave, a leading Southeast Asian fintech platform backed by Sequoia Capital and acquired by Pine Labs, a unicorn company. Joel has been instrumental in accelerating digital payments and financial services for millions of consumers and merchants. Previously, Joel was the founder of GroupsMore, which was acquired by Groupon. While at Groupon, Joel headed up its Asia Pacific business, overseeing more than 2,000 employees. Joel’s entrepreneurial journey started out by co-founding Says.com, one of Malaysia’s largest digital news platforms. Joel is also a Board Director for the Institute of Corporate Directors Malaysia, promoting excellence in corporate governance. His entrepreneurial success and leadership led to his recognition as Ernst & Young Emerging Entrepreneur of the Year (Malaysia) in 2012, and as a Young Global Leader by the World Economic Forum in 2013.

Mr. Vanderveen has had a successful 30-year track record in beverage, nutrition, and technology, leading disruptive change at both private and public companies. From 2022 until recently, he was CEO of Nirvana Water Sciences, where he developed a team of industry beverage, functional beverage, and supplement experts to transform the brand, product portfolio, go-to-market strategy, and execution of the business.

From 2002 to 2015, Mr. Vanderveen was the founder and CEO of XS Worldwide, a company with a portfolio of energy drinks and sports nutrition products. XS partnered with Amway Corporation and became the fastest-growing business segment and category for the world’s largest direct seller, reaching annual sales over $400 million with distribution in more than 60 countries. XS was sold to Amway in 2015, where Mr. Vanderveen served as Vice President and Global General Manager for the XS brand, achieving maximum earn-out through 2018.

Mr. Vanderveen is also an advisor and limited partner at RX3 Growth Partners, a private equity firm that partners with consumer brands and other leading investment firms to maximize value by leveraging its unique influencer base of athletes, celebrities, and thought leaders, and is a general partner in LLB Global Fund, an international arbitration fund in partnership with French law firm, Lazareff Le Bars.

Samantha Kwok is the Chief of Staff to Group CEO and Vice President, Operations & People, of Prenetics, and is responsible for all the overall people strategy, global talent acquisition, leadership development, organizational design, and delivering an inclusive employee and candidate experience which reflects Prenetics vision, mission and values. Samantha works with leaders across Prenetics’ different lines of business to support their dynamic needs, and is focused on developing and implementing strategies which drive business results and foster a positive and creative work environment. Prior to Prenetics, Samantha had extensive recruitment and HR consulting experience across Greater China, advising and consulting for many of China’s largest tech companies including Alibaba, VIPKID, Didi, Bytedance, Binance and Xiaomi, Daimler and FGS Global through her own entrepreneurial ventures. Samantha was also Chief of Staff, People and Operations at multiple tech startups, consumer brands and B2B platforms, helping several international brands launch and expand successfully throughout APAC. Samantha holds a degree in political, economic and social sciences from the University of Sydney.

Dr. Senthil Sundaram is the Chief Clinical Officer of Prenetics, and is responsible for overseeing the clinical policies. Dr. Sundaram is highly recognised for his experience as a physician-scientist, having led numerous genetic research programs in the USA. Dr. Sundaram has discovered genetic mutations and rare genetic variants causing different neurological diseases using cutting edge next-generation sequencing technologies such as whole exome sequencing. Dr. Sundaram’s research articles have been published in reputed, high-impact journals such as Neurology, Annals of Neurology, Cerebral Cortex and others. Dr. Sundaram’s research works were funded by the National Institute of Health (NIH), USA. Dr. Sundaram also served as a reviewer of different journals and NIH study sections.

Dr. James DiNicolantonio is the Chief Nutrition Officer of Prenetics.  His role primarily focuses on product development of evidence based nutraceuticals. From 2010 to 2020 he worked at Wegmans Food Markets where he served as a Clinical and Specialty Pharmacist and helped to build Wegmans Supplement and Active Nutrition lines.  From 2013 to 2023 he served as a Cardiovascular Research Scientist at Saint Luke's Mid America Heart Institute publishing over 250 academic papers primarily on nutrition and nutraceuticals.  He was also the Associate Editor of BMJ Open Heart, a cardiovascular journal published in partnership with the British Cardiovascular Society from 2013 to 2023.  From 2020 to 2022 Dr. DiNicolantonio served as the Director of Scientific Affairs at AIDP, a leading ingredient supplier to the supplement industry.  Dr. DiNicolantonio brings over 15 years of experience in the supplement space and has published over 10 books on health and nutrition.

Danny Yeung is the Co-Founder of Prenetics and has served as Chief Executive Officer since its inception in 2014. Mr. Yeung’s journey into healthcare started as a way to utilize his extensive entrepreneurial career into making an impact for society. Mr. Yeung’s vision from day 1 was to always turn Prenetics into a global health company, recruiting the best talent, and to give everyone the power to be in control of their own health.

Prior to Prenetics, Mr. Yeung was a Founding Partner at SXE Ventures, having led multiple investments in genetic testing companies and in Honey Science, which was acquired by Paypal for US $4 billion in 2019. Mr. Yeung had also founded uBuyiBuy in 2010, which was subsequently acquired by Groupon. Prior to leaving Groupon in early 2014, Mr. Yeung served as CEO of Groupon East Asia, leading it to be the largest e-commerce company in the region. Mr. Yeung’s entrepreneurial journey started at the age of 25 when he ventured into franchising Hong Kong dessert chain “Hui Lau Shan” into the USA. After exiting Hui Lau Shan, Mr. Yeung successfully ventured into hospitality furniture and executed multi-million-dollar projects with MGM globally. Mr. Yeung’s life motto is “Play Hard, Work Harder”.

Mr. Vanderveen has had a successful 30-year track record in beverage, nutrition, and technology, leading disruptive change at both private and public companies. From 2022 until recently, he was CEO of Nirvana Water Sciences, where he developed a team of industry beverage, functional beverage, and supplement experts to transform the brand, product portfolio, go-to-market strategy, and execution of the business.

From 2002 to 2015, Mr. Vanderveen was the founder and CEO of XS Worldwide, a company with a portfolio of energy drinks and sports nutrition products. XS partnered with Amway Corporation and became the fastest-growing business segment and category for the world’s largest direct seller, reaching annual sales over $400 million with distribution in more than 60 countries. XS was sold to Amway in 2015, where Mr. Vanderveen served as Vice President and Global General Manager for the XS brand, achieving maximum earn-out through 2018.

Mr. Vanderveen is also an advisor and limited partner at RX3 Growth Partners, a private equity firm that partners with consumer brands and other leading investment firms to maximize value by leveraging its unique influencer base of athletes, celebrities, and thought leaders, and is a general partner in LLB Global Fund, an international arbitration fund in partnership with French law firm, Lazareff Le Bars.

Mr. Ben Cheng has been proposed as an Executive Board Member and CEO of C Capital AG. He serves as the President and CEO of C Capital, a global asset management platform specializing in private equity, private credit fund and blockchain hedge fund strategies. Under his leadership, C Capital has made significant strides in the investment landscape, focusing on transformative opportunities across various sector.

With extensive experience in venture capital and private equity, Mr. Cheng has played a pivotal role in high-profile investments, including CASETiFY, the fastest-growing global tech accessories brand; XiaoPeng (NYSE: XPEV), a leading Chinese electric vehicle manufacturer; Animoca Brands, a multinational blockchain technology; NOTHING, a UK-based consumer electronics manufacturer; Lalamove, a prominent Chinese on-demand logistics firm. He is also a board member of Prenetics Global Limited (Nasdaq: PRE) and holds a Non-executive Director position at Ocean Line Port Development Limited (8502.HK).

In addition to his operational roles, Mr. Cheng actively contributes to the community as a committee member of Hong Kong Trade Development Council Mainland Business Advisory Committee and the Venture Committee of Hong Kong Venture Capital and Private Equity Association. He is also a committee member of The LRC Charitable Foundation (LRCCF).

Prior to C Capital, Mr. Cheng honed his expertise as an investment banker at Bank of America Merrill Lynch and Standard Chartered Bank, where he was involved in landmark transactions such as the US$3.3 billion take-private of WuXi PharmaTech, Temasek’s US$5.7 billion investment in Watson’s and the US$2.1 billion acquisition of ING's insurance business in Hong Kong, Macau and Thailand.

Mr. Cheng’s diverse experience and strategic vision position him as a key leader in the investment community, driving innovation and growth at C Capital and beyond.

Mr. Cheung brings extensive leadership experience in digital asset operations and financial technology to Prenetics' Board. He previously served as Chief Operating Officer of OKEx, one of the world's largest cryptocurrency exchanges, where he managed global operations for a platform handling billions of dollars in daily trading volume. Mr. Cheung currently serves as Co-Founder and Chief Executive Officer of OEX, a digital asset trading platform, and Co-Founder and Chief Executive Officer of PredicXion, a blockchain-based and AI-Powered prediction market. Mr. Cheung and Prenetics CEO Danny Yeung previously collaborated at Groupon approximately 15 years ago, establishing a proven working relationship and mutual trust that enhances board effectiveness. His appointment strengthens Prenetics' strategic capabilities as the Company executes on its Bitcoin treasury strategies and digital asset initiatives.

Dr. James DiNicolantonio is the Chief Nutrition Officer of Prenetics.  His role primarily focuses on product development of evidence based nutraceuticals. From 2010 to 2020 he worked at Wegmans Food Markets where he served as a Clinical and Specialty Pharmacist and helped to build Wegmans Supplement and Active Nutrition lines.  From 2013 to 2023 he served as a Cardiovascular Research Scientist at Saint Luke's Mid America Heart Institute publishing over 250 academic papers primarily on nutrition and nutraceuticals.  He was also the Associate Editor of BMJ Open Heart, a cardiovascular journal published in partnership with the British Cardiovascular Society from 2013 to 2023.  From 2020 to 2022 Dr. DiNicolantonio served as the Director of Scientific Affairs at AIDP, a leading ingredient supplier to the supplement industry.  Dr. DiNicolantonio brings over 15 years of experience in the supplement space and has published over 10 books on health and nutrition.

Dr. Dawn Mussallem is a distinguished consultant in the Division of Hematology Oncology at Mayo Clinic, where she has served as a clinician for over 20 years, and an Assistant Professor of Medicine. She is a board-certified lifestyle medicine breast specialist at The Robert and Monica Jacoby Center for Breast Health and founded the Integrative Medicine and Breast Health Program at Mayo Clinic Florida.
 
A stage IV cancer survivor diagnosed three months into medical school, Dr. Mussallem’s personal journey is a testament to resilience and determination. In 2021, she underwent a heart transplant and remarkably became the first person to run a marathon one year post-transplant. Internationally recognized for her work in cancer prevention and integrative oncology, she is a prolific speaker and author. Her dedication to patient care and innovative approaches align perfectly with Prenetics' mission, making her an invaluable addition to the Medical Advisory Board.

Dr. James L. Green is the former Chief Scientist of NASA, where he dedicated an impressive 42 years to advancing space science and exploration. During his tenure, Dr. Green contributed to numerous groundbreaking missions, including the Mars Rover landings, the New Horizons mission to Pluto, and the Juno mission to Jupiter. He played a pivotal role in the development of planetary defense strategies and was instrumental in fostering international collaborations for space research.

Dr. Green's extensive experience in managing large-scale scientific projects and his deep understanding of cutting-edge technologies bring a unique perspective to Prenetics. His work at NASA also included leveraging space research for health innovations, such as studying the effects of space travel on the human body and accelerated aging. His expertise in scientific innovation and strategic vision will be invaluable in advancing Prenetics' mission to revolutionize healthcare through precision diagnostics and personalized medicine.

David L. Katz, MD, MPH, FACPM, FACP, FACLM, is a specialist in Internal Medicine, Preventive Medicine/Public Health, and Lifestyle Medicine, with particular expertise in nutrition. He earned his BA at Dartmouth College (1984); his MD at the Albert Einstein College of Medicine (1988); and his MPH from the Yale University School of Public Health (1993).  

Katz is the founder and former director of Yale University’s Yale-Griffin Prevention Research Center (1998-2019); Past President of the American College of Lifestyle Medicine; Founder of the non-profit True Health Initiative; and Founder of Diet ID, Inc, and Chief Medical Officer for Tangelo. He is a Fellow of the American College of Preventive Medicine; the American College of Physicians; the American College of Lifestyle Medicine; and Morse College, Yale University.

The recipient of numerous awards for teaching, writing, and contributions to public health, Katz was a 2019 James Beard Foundation Award nominee in health journalism, is a 2023 recipient of a Lifetime Achievement Award from the Doctors’ World Gala, and has received three honorary doctorates.  

He holds multiple US patents; has roughly 250 peer-reviewed publications; and has authored/co-authored 19 books to date including multiple editions of leading textbooks in nutrition, preventive medicine, and epidemiology.

Dr. Suzanne Devkota is a leading expert in microbiome research and its impact on human health, with over 15 years of experience in the field. She is an Associate Professor at Cedars-Sinai Medical Center and the Director of the Microbiome Research Institute. Dr. Devkota’s groundbreaking work focuses on understanding the role of the gut microbiome in chronic diseases, including inflammatory bowel disease, obesity, and diabetes. She has published extensively in top scientific journals and is a sought-after speaker at international conferences.

Dr. Devkota’s research emphasizes the critical connection between the microbiome and overall health, highlighting the potential for microbiome-based therapies. Her insights into how diet and lifestyle influence the gut microbiome align closely with Prenetics' mission to advance health through innovative diagnostics and personalized medicine. Dr. Devkota’s expertise in microbiome science will be invaluable in helping Prenetics develop cutting-edge solutions to improve health outcomes and foster preventative care.

Prof. Stephen Anton is a renowned expert in aging and metabolic health, with over 20 years of experience in the field. He is a Distinguished Professor at the University of Florida with a primary appointment in the Department of Physiology and Aging. Prof. Anton’s research focuses on the interplay between lifestyle factors, metabolic health, and aging, with a particular emphasis on the benefits of caloric restriction, intermittent fasting, and physical activity. He has authored numerous scientific publications and is a frequent speaker at national and international conferences.

Prof. Anton’s extensive work highlights the potential of lifestyle interventions in promoting healthy aging and preventing metabolic diseases. His insights into the mechanisms of aging and metabolic regulation are highly relevant to Prenetics' mission of leveraging advanced diagnostics and personalized health strategies. Prof. Anton’s expertise is invaluable in helping Prenetics develop innovative solutions to enhance healthspan and improve metabolic health outcomes.

Dr. Jeremy London is a distinguished cardiothoracic surgeon renowned for his expertise in cardiac surgery and minimally invasive procedures. With 26 years of experience treating complex heart conditions, Dr. London emphasizes personalized patient care and integrates advanced surgical techniques to optimize cardiovascular health and recovery.

Recognized for his compassionate and patient-centered approach, Dr. London excels at translating complex cardiac procedures into clear, understandable guidance, empowering patients to actively participate in their care. Dr. London’s commitment to excellence and his dedication to patient education have established him as a trusted figure in the health and wellness community, helping individuals achieve healthier, happier lives.

Dr. Amy Shah is a double board-certified MD specializing in integrative medicine and a nutrition specialist. She works in clinical medicine, allergy/immunology, and over the last 10 years has developed a world-renowned wellness education platform, successfully launched a growing collection of health and wellness products, written bestselling books, including I’m So Effing Hungry and I’m So Effing Tired, and has made numerous national network appearances. She works to discover less invasive interventions, promote wellness, and teach others how to impact their health via nutrition and exercise -- using medication as a last resort. Her goal is to empower people to “save themselves” through nutrition and lifestyle changes.

Passionate about helping people take control of their health, Dr. Shah offers a wealth of knowledge on how to optimize vitality through nutrition, fasting, and lifestyle adjustments. Her expertise in gut health and hormone balance has made her a sought-after figure for individuals seeking to enhance their health naturally. Dr. Shah’s balanced, mindful approach resonates with a growing community of wellness enthusiasts who prioritize longevity and sustainable, science-based health practices.

Dr. Ara Suppiah is a globally respected sports physician and performance strategist known for helping elite athletes perform at their highest level—consistently, intelligently, and without burning out.

Born in Malaysia, trained in the UK, and now based in the U.S., Ara blends deep medical expertise with cutting-edge tools from neuroscience, functional medicine, genetics, biomechanics, and AI. He’s worked with 7 World No.1s, 35 major golf wins, Olympic medalists, and multiple Ryder Cup teams. As Head of Medical Services for LIV Golf, he’s building world-class systems to keep the game's best at the top of theirs.

He created the Functional Sports Medicine Matrix, a systems-based framework to optimize recovery, energy, resilience, and performance. Through his Masterclass and consulting, he teaches other professionals how to think in systems—not symptoms.

Despite his global reputation, Dr. Ara still works as an ER physician in Orlando and mentors the next generation of clinicians as an assistant professor at the University of Central Florida.

His mission is big: to empower one million athletes using the best of authentic intelligence + artificial intelligence.

Darshan Shah, MD, is a health and wellness specialist, board-certified surgeon, published author, and founder of Next Health, the world's first and largest Health Optimization and Longevity clinic. Dr. Shah is a board certified surgeon who has performed over 20,000 surgical procedures, including trauma and complex reconstructive procedures. As a Longevity Medicine specialist, he has advised thousands of patients on how to optimize their well-being and extend their healthspan and lifespan.

Dr. Shah began his career at an accelerated MD program and earned his medical degree at the age of 21, becoming one of the youngest doctors in the United States. He continued his training at the Mayo Clinic, one of the most prestigious medical institutes in the country.

After earning his board certification, he opened medical/surgical centers throughout California, started four other companies in the Health and Wellness space, and has published a book, authored numerous papers and patented medical devices.

Dr. Shah’s belief in continual education and self-improvement has earned him alumni status at Harvard Business School, Singularity University, and other prestigious institutions. His passion is educating people on the topics of adding healthspan to your lifespan, having done over 100+ speaking engagements and hosting the critically acclaimed podcast Extend.

Simon Hill, a physiotherapist and nutrition scientist, is dedicated to simplifying health and nutrition information. He began his career interested in the physiology and anatomy related to optimal athletic performance. Then, encouraged by his Dad’s heart attack, he turned his attention to nutrition’s role in preventing disease and optimising health. Concerned about misleading wellness industry trends, he completed a Master of Science in Human Nutrition at Deakin University.

Today, Simon hosts a podcast featuring experts translating research into practical advice. He authored “The Proof is in the Plants,” advocating for a plant-rich diet based on current nutrition research.

On it’s debut week The Proof is in the Plants was the #1 non-fiction book in Australia. He continues to deepen his understanding of human health by being actively involved in research investigating the links between nutrition and mental health.

His podcast, The Proof, a space where he sits down with domain-specific experts, has surpassed 40 million listens, exploring various lifestyle factors impacting well-being. Simon now conducts immersive longevity experiences, aiming to empower people to live better for longer.

Prof. Mok will lead the SAB and currently serves as Chairman of the Department of Clinical Oncology of Chinese University of Hong Kong, is a non-executive director of AstraZeneca plc (LON:AZN), and an independent director of HUTCHMED (China) Limited (Nasdaq/AIM: HCM; HKEX: 0013). His main research interest focuses on biomarker and molecular targeted therapy in lung cancer.

Prof. Mok was the Principal Investigator and first author on the landmark IRESSA® Pan-Asia Study (IPASS), which was the first study that confirmed the application of precision medicine for advanced lung cancer. He has also led and co-led multiple studies including the FASTACT 2, IMPRESS, ARCHER 1050, ALEX and AURA 3. These projects address various aspects on management of EGFR mutation positive lung cancer, and have played a significant role in defining current practice. Prof. Mok has also engaged in clinical research on ALK positive lung cancer and immunotherapy. The series of clinical trials, led or co-led by Professor Mok, have defined precision medicine. His work has been adopted by multiple international guidelines including NCCN, AMP/IASLC/CAP, ASCO and ESMO.

Prof. Pasi Jänne is a globally renowned translational thoracic medical oncologist at the Dana Farber Cancer Institute and Professor of Medicine at Harvard Medical School. He is also the Director of the Lowe Center for Thoracic Oncology and the Director of the Belfer Center for Applied Cancer Science. Prof. Jänne's research combines laboratory-based study with translational research in clinical trial of novel therapeutic agents in patients with lung cancer. He has made seminal therapeutic discovery including co-discovery of EGFR mutations and has led the development of therapeutic strategies for patients with EGFR mutant lung cancer.

Prof. Pasi Jänne's translational research work also led to the successful development of HER3-ADC in NSCLC and combination with Osimertinib to further enhance the potential efficacy of HER3-ADC. Prof. Jänne has received multiple awards for his work including from the AACR, ESMO and ASCO.

Prof. Yang is the former President of Taiwan University and has been a professor in the department of internal medicine at the College of Medicine for 27 years. He has also served as the Director of the Advisory Office for the Ministry of Education and as Dean for the College of Medicine at Taiwan University. Dr. Yang was honoured with the Joseph W. Cullen Prevention/Early Detection Award at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer.

Prof. Yang is a pioneer and leader in pulmonary ultrasound diagnostics and therapeutics that have revolutionized the management of pulmonary diseases which include lung cancer. He has led a research group to develop the method for detection and quantification circulating cancer cells in peripheral blood and to better predict the prognosis and response to treatment for lung cancer patients. His has led a research group to discover novel genes and pathways that associated with lung cancer pathogenesis and progression. They identified specific gene expression and microRNA signatures that can assist to predict the treatment outcome and may be beneficial for personalized therapy of lung cancer patients.